Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer

Experimental Lung Research

Volumn 36, Issue 9, 2010, Pages 531-537

  McMillen, Elizabeth ^a   Ye, Fei ^a   Li, Guanghu ^b   Wu, Yong ^b   Yin, Guanghao ^b   Liu, Wei ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

EGFR; immunohistochemistry; mutation analysis; NSCLC; predictive biomarkers; TKIs

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER SURGERY; CHINESE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SMOKING;

EID: 77957980349     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2010.482176     Document Type: Article

References (32)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and sur vivorship. Mayo Clin Proc. 2008;83:584-594.
2. Kris MG, Natale RB, Herbst RS, et al.: Effcacy of geftinib, an inhibitor of the epidermal growth factor receptor tyrosine ki-nase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158.
3. Han SW, Kim TY, Hwang PG, et al.: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with geftinib. J Clin Oncol. 2005;23:2493-2501.
4. Zhang X, Chang A: Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci. 2008;5:209-217.
5. Chang A, Parikh P, Thongprasert S, et al.: Geftinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006;1:847-855.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
7. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med. 2004;350:2129-2139.
8. Tsao MS, Sakurada A, Cutz JC, et al.: Erlotinib in lung cancer\-molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
9. Takano T, Ohe Y, Sakamoto H, et al.: Epidermal growth factor receptor gene mutations and increased copy numbers predict geftinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23:6829-6837.
10. Shigematsu H, Lin L, Takahashi T, et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346. (Pubitemid 40425952)
11. Fukuoka M, Yano S, Giaccone G, et al.: Multi-institutional ran domized phase II trial of geftinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237-2246.
12. Miller VA, Kris MG, Shah N, et al.: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gef-tinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:1103-1109.
13. Wu YL, Zhong WZ, Li LY, et al.: Epidermal growth factor receptor mutations and their correlation with geftinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2007;2: 430-439.
14. Mu XL, Li LY, Zhang XT, et al.: Geftinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res. 2005;11:4289-4294.
15. Endoh H, Ishibashi Y, Yamaki E, et al.: Immunohistochemi-cal analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer. 2009;63:241-246.
16. Levkowitz G, Waterman H, Ettenberg SA, et al.: Ubiqui-tin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4:1029-1040.
17. Mosesson Y, Shtiegman K, Katz M, et al.: Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyu-biquitylation. J Biol Chem. 2003;278:21323-21326.
18. Chen YR, Fu YN, Lin CH, et al.: Distinctive activation patterns in constitutively active and geftinib-sensitive EGFR mutants. Oncogene. 2006;25:1205-1215.
19. Han W, Zhang T, Yu H, Foulke JG, Tang CK: Hypophospho-rylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther. 2006;5:1361-1368.
20. VanMeter AJ, Rodriguez AS, Bowman ED, et al.: Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics. 2008;7:1902-1924.
21. Okabe T, Okamoto I, Tamura K, et al.: Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and ampli-fcation. Cancer Res. 2007;67:2046-2053.
22. Turner BC, Krajewski S, Krajewska M, et al.: BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol. 2001;19:992-1000.
23. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO: E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic signifcance. Histopathology. 2005;46:685-693.
24. Morita S, Okamoto I, Kobayashi K, et al.: Combined survival analysis of prospective clinical trials of geftinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2009;15:4493-4498.
25. Sequist LV, Martins RG, Spigel D, et al.: First-line gef-tinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26: 2442-2449.
26. He C, Liu M, Zhou C, et al.: Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to geftinib in patients with non-small cell lung cancer. Int J Cancer. 2009;125:2393-2399.
27. Shih JY, Gow CH, Yu CJ, et al.: Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to geftinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer. 2006;118:963-969.
28. Yu J, Kane S, Wu J, et al.: Mutation-specifc antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023-3028.
29. Sordella R, Bell DW, Haber DA, Settleman J.: Geftinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163-1167.
30. Furukawa M, Nagatomo I, Kumagai T, et al.: Geftinib-sensitive EGFR lacking residues 746-750 exhibits hypophos-phorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis. DNA Cell Biol. 2007;26:178-185.
31. Emery IF, Battelli C, Auclair PL, Carrier K, Hayes DM: Response to geftinib and erlotinib in Non-small cell lung cancer: a restrospective study. BMC Cancer. 2009;9:333.
32. Hijiya N, Miyawaki M, Kawahara K, et al.: Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to geftinib in pulmonary adenocarcinoma. Hum Pathol. 2008;39:316-323.